Asia Green Biotechnology Corp. announced that it has obtained additional financing and completed the next payment to facilitate its continuing scientific trials activities with respect to treatments for migraine and related health issues being developed by Pathway RX Inc. and Swysh Inc., Asia Green's research and development partners. This action comes as a consequence of the partners' completing the Health Canada instructions to revise the clinical trial application, to provide GMP-certified gel caps necessary to continue with the active phase of the human trials process.

If the results of the first phase of the clinical trials are positive and the various parties agree, a second and more detailed phase of clinical trial will be initiated. Migraine Study: This development is a significant part of a wider program to have the exclusive hemp and related cannabidiol varieties that the Company has access to by virtue of its exclusive licensing agreements with Pathway RX Inc. and Swysh Inc., and possibly other versions of the strains, studied for their efficacy in humans and eventually approved and applied as new drugs and over-the-counter health products. The particular focus of this study and further studies which may be derived from it is on the ability of an element of a proprietary hemp strain to treat and minimize symptoms in those suffering from migraine headaches.

In addition to the suffering of individuals, migraine also has an impact on society which can be measured in both direct costs (medical care etc.) and indirect costs (missed work and disability at work).